Semanteon Capital Management LP Buys Shares of 13,755 DexCom, Inc. (NASDAQ:DXCM)

Semanteon Capital Management LP purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 13,755 shares of the medical device company's stock, valued at approximately $922,000.

Other large investors have also recently modified their holdings of the company. Canada Pension Plan Investment Board raised its holdings in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock valued at $75,471,000 after buying an additional 435,401 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after buying an additional 353,019 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company's stock valued at $66,352,000 after buying an additional 345,114 shares in the last quarter. Bellevue Group AG raised its holdings in shares of DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company's stock valued at $169,380,000 after buying an additional 306,604 shares in the last quarter. Finally, Magnetar Financial LLC purchased a new position in shares of DexCom during the 2nd quarter valued at about $31,793,000. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Down 1.8 %

Shares of NASDAQ DXCM traded down $1.34 during mid-day trading on Monday, hitting $72.10. 5,564,987 shares of the stock traded hands, compared to its average volume of 3,912,946. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The stock has a fifty day moving average price of $70.11 and a 200-day moving average price of $97.65. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market cap of $28.67 billion, a price-to-earnings ratio of 46.69, a PEG ratio of 2.26 and a beta of 1.18.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the company posted $0.34 earnings per share. The company's revenue for the quarter was up 15.3% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday. Oppenheimer decreased their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Finally, JPMorgan Chase & Co. boosted their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.